Viking Therapeutics

VKTXNASDAQHigh Risk

Developing next-generation GLP-1 receptor agonists and thyroid hormone receptor beta agonists. Lead obesity program VK2735 is a dual GLP-1/GIP receptor agonist designed to compete with Eli Lilly's tirzepatide (Mounjaro/Zepbound) with potentially superior weight loss and a subcutaneous or oral formulation.

Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

Obesity NASH/MASH Metabolic Disease

Market cap

Mid cap

Cash position

$502M as of Q2 2026

~13 months runway (derived)

Revenue status

pre revenue

Pipeline assets

3 programs

Trade VKTX commission-free on Webullvia Webull · Affiliate

What does Viking Therapeutics do?

Viking Therapeutics is one of the most talked-about small biotech companies in the market right now, and the reason is simple: they may have cracked the code on a weight-loss drug that rivals the best from Eli Lilly and Novo Nordisk — the two giants that currently dominate the obesity market. Their lead drug, VK2735, works similarly to Mounjaro/Zepbound (Lilly's blockbuster): it mimics two gut hormones called GLP-1 and GIP that tell your brain you're full and your body to burn fat. In a Phase 2 trial, patients lost an average of 14.7% of their body weight in just 13 weeks. To put that in context, most weight-loss drugs take 6-12 months to show that level of results. Extrapolating Viking's trajectory suggests their drug could potentially match the ~22% weight loss that Zepbound achieves over a longer period. But here's what really excites investors: Viking is also developing an oral (pill) version of the same drug. Right now, all the top weight-loss drugs are injections, which many patients hate. If Viking can deliver comparable weight loss in a pill form, it would be revolutionary. Early Phase 1 data for the pill version looked promising. The investment case is straightforward: if VK2735 works in Phase 3, Viking becomes an acquisition target. Pfizer, Roche, AstraZeneca — any large pharma company without an obesity franchise would likely pay a substantial premium to buy Viking rather than develop their own drug from scratch. The obesity market is projected to be worth over $100 billion, so there's plenty of room for a third major player. The risk is equally straightforward: this is a pre-revenue company with 90 employees betting everything on one molecule. Phase 2 results don't always hold up in Phase 3. And competing against Lilly and Novo is like a startup trying to out-Google Google.

What to watch

Oral VK2735 Phase 2 data is the single most important catalyst in H2 2026 — double-digit weight loss from a pill would be seismic

Phase 3 VENTURE enrollment pace — faster enrollment signals strong investigator interest and patient demand

Any M&A rumors or partnership announcements — Viking at this stage is a classic acquisition candidate

Competitor data from Amgen (MariTide), Structure Therapeutics (oral GPCR agonist), and Lilly (orforglipron) — these set the bar Viking must clear

Cash burn rate trajectory — can they complete Phase 3 with existing cash or will they need to raise?

Pipeline

Drug	Indication	Phase	Expected data
VK2735 (subcutaneous)	Obesity / overweight with comorbidities	Phase 3	2027 (Phase 3 VENTURE topline)	▼
VK2735 (oral)	Obesity / overweight with comorbidities	Phase 2	H2 2026	▼
VK2809	NASH/MASH (non-alcoholic steatohepatitis)	Phase 2	Partnered or deprioritized relative to VK2735	▼

Investment thesis

Bull case

Viking has arguably the best Phase 2 obesity data of any company outside Lilly and Novo. VK2735 showed 14.7% weight loss at just 13 weeks — a rate that, if sustained, could match or beat Zepbound. The oral formulation is potentially even more valuable because it removes the injection barrier. With $930M in cash, they can fully fund Phase 3 without dilution. The obesity market is the largest new drug market in a generation at $100B+. Viking is the most likely acquisition target in the space — Pfizer, AstraZeneca, Roche, or any large pharma without an obesity franchise would pay a massive premium. Even at a $10B acquisition price, that represents significant upside from current levels.

Bear case

Viking is a 90-person company trying to compete against two of the largest pharmaceutical companies on Earth (Lilly and Novo). Phase 2 to Phase 3 is where most obesity drugs fail — smaller trials can look impressive while larger trials regress to the mean. The 13-week Phase 2 data doesn't tell us about durability, weight regain, or long-term safety. If Phase 3 results come in materially below Zepbound, Viking loses its competitive thesis entirely. The oral program is even earlier and oral GLP-1s have historically shown less weight loss than injectable forms. The $930M cash sounds like a lot, but running a global Phase 3 obesity trial costs $500M+. There's no revenue, no other approved products, and the entire company's value rests on one molecule.

Key upcoming catalysts

VK2735 oral Phase 2 data readout

H2 2026

Unverified — this date has not been checked against a primary source.

Data ReadoutStock moving

VK2735 SC Phase 3 VENTURE enrollment completion

2026

Unverified — this date has not been checked against a primary source.

Data ReadoutSignificant

Potential partnership or M&A activity

2026-2027

Unverified — this date has not been checked against a primary source.

Data ReadoutStock moving

VK2735 SC Phase 3 VENTURE topline results

2027

Unverified — this date has not been checked against a primary source.

Data ReadoutStock moving

Risk factors

⚠

Phase 3 obesity results come in below Phase 2 levels, which is common due to larger, more diverse patient populations

⚠

Oral VK2735 shows significantly less weight loss than injectable, undermining the oral thesis

⚠

Eli Lilly or Novo Nordisk launch next-gen products that raise the efficacy bar before Viking can reach market

⚠

Safety signals emerge in longer-duration studies that weren't apparent in 13-week Phase 2

⚠

No acquirer steps up, forcing Viking to commercialize independently — a massive operational challenge for a 90-person company

Chart VKTX on TradingView — used by 30M+ tradersvia TradingView · Affiliate

Comparable companies

LLYNVOGPCRAMGNALT

Financial snapshot

These figures are drafted by our AI pipeline, not read from SEC filings. Confirm anything you would act on against the company's latest 10-Q or 10-K.

Cash

$502M as of Q2 2026

Q2 2026 — 1 quarter ago

Quarterly burn

$120M

Cash runway

~13 months

$502M ÷ $120M per quarter

Revenue

pre revenue

Institutional ownership

55%

Recent offering

$900M raised via equity offering in early 2024 to fund Phase 3 obesity program

Source: SEC filings. Cash and operating cash flow read from VKTX’s SEC XBRL filings, most recently filed 2026-07-29. Read the filings on EDGAR.

Cash against the next catalyst

Tight against cash

Cash reaches roughly Q2 2027 on the disclosed figures, about 1 quarter past this Q1 2027 catalyst. A disappointing result would leave little room to fund what comes next.

Derived from $502M ÷ $120M per quarter, both self-reported.
Burn usually rises as a programme moves through late-stage trials, so this is an upper bound.

This is the arithmetic between two dates, not a forecast. Companies raise early from strength, delay programmes, partner, or borrow.

Sponsor's late-stage trial record

Viking Therapeutics has 7 Phase 2 or 3 studies on ClinicalTrials.gov: 5 completed, 2 ongoing.

Completed

Stopped early

Ongoing

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-13 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.